Cargando…

Gene therapy for arthritis – where do we stand?

The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that su...

Descripción completa

Detalles Bibliográficos
Autor principal: Chernajovsky, Yuti
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297573/
https://www.ncbi.nlm.nih.gov/pubmed/16277696
http://dx.doi.org/10.1186/ar1823
_version_ 1782126218119741440
author Chernajovsky, Yuti
author_facet Chernajovsky, Yuti
author_sort Chernajovsky, Yuti
collection PubMed
description The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments.
format Text
id pubmed-1297573
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12975732005-12-01 Gene therapy for arthritis – where do we stand? Chernajovsky, Yuti Arthritis Res Ther Commentary The successful use of biologicals in the treatment of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis has had a major impact on the management of these conditions. The challenge in the development of gene therapy as an alternative to these current treatments is to demonstrate that such therapy is more advantageous for patients from the therapeutic and safety points of view. Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments. BioMed Central 2005 2005-09-14 /pmc/articles/PMC1297573/ /pubmed/16277696 http://dx.doi.org/10.1186/ar1823 Text en Copyright © 2005 BioMed Central Ltd
spellingShingle Commentary
Chernajovsky, Yuti
Gene therapy for arthritis – where do we stand?
title Gene therapy for arthritis – where do we stand?
title_full Gene therapy for arthritis – where do we stand?
title_fullStr Gene therapy for arthritis – where do we stand?
title_full_unstemmed Gene therapy for arthritis – where do we stand?
title_short Gene therapy for arthritis – where do we stand?
title_sort gene therapy for arthritis – where do we stand?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297573/
https://www.ncbi.nlm.nih.gov/pubmed/16277696
http://dx.doi.org/10.1186/ar1823
work_keys_str_mv AT chernajovskyyuti genetherapyforarthritiswheredowestand